18-24月龄中国儿童接种Sabin株灭活脊髓灰质炎疫苗加强针的免疫原性与批间一致性:一项Ⅳ期临床试验
一项Ⅳ期随机双盲临床试验中,1200名2月龄婴儿完成3剂基础免疫后,1129人于18-24月龄接种第4剂sIPV加强免疫,1100人评估免疫原性;加强后三型抗体血清阳性率均达100.0%,GMT分别为8343.6、5039.6、5492.0,批间GMT比值在0.67至1.50之间符合免疫等效标准,不良反应发生率23.0%,未报告SUSAR。
要点
- 基础免疫后1年,抗脊髓灰质炎病毒1、2、3型血清阳性率分别为99.9%、98.0%、98.2%。
- 18-24月龄加强后三型血清阳性率均达100.0%,GMT分别为8343.6、5039.6、5492.0。
- 加强后各批间GMT比值在0.67至1.50之间,符合免疫等效标准。
核心结论
- sIPV基础免疫后1年抗体逐渐衰减,尤其2型抗体降至很低水平,提示18-24月龄儿童加强免疫的重要性。
- 加强接种可大幅提升抗体水平,通过补充当前真实世界中抗脊髓灰质炎病毒2型免疫缺口,保护儿童免受WPV和VDPV感染的潜在风险。
研究设计与样本
- Ⅳ期随机双盲临床试验,1200名2月龄参与者于2、3、4月龄接种三剂连续sIPV完成基础免疫。
- 1200名参与者中1129人于18-24月龄接种第4剂sIPV加强免疫,1100人评估免疫原性。
主要发现
- 基础免疫后1年,抗脊髓灰质炎病毒1、2、3型中和抗体血清阳性率分别为99.9%、98.0%、98.2%,GMT分别为557.0、146.1、362.0。
- 18-24月龄加强免疫后,三型血清阳性率均达100.0%,GMT分别为8343.6、5039.6、5492.0。
- 抗脊髓灰质炎病毒2型抗体GMT基础免疫后为230.4,基础免疫后1年维持于146.1,加强免疫后升至5039.6。
- 加强免疫后各批组间GMT比值在0.67至1.50之间,符合免疫等效标准。
- 不良反应发生率为23.0%,与Ⅲ期试验相当但发生率更低,本研究未报告SUSAR。
关键数值与推荐
- 加强免疫后三型血清阳性率均达100.0%。
- 加强免疫后抗脊髓灰质炎病毒1、2、3型GMT分别为8343.6、5039.6、5492.0。
- 各批组间加强免疫后GMT比值在0.67至1.50之间,符合免疫等效标准。
- 不良反应发生率23.0%。
临床怎么用
- 原文结论提示18-24月龄儿童加强免疫的重要性,加强接种可大幅提升抗体水平并补充抗脊髓灰质炎病毒2型免疫缺口。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There has been no data on the immunogenicity and safety of the 4th booster dose of the sIPV immunization in 18-24 months old children in post-marketing studies of large cohort providing with robust results. METHOD: In a phase Ⅳ randomized, double-blinded clinical trial, 1200 participants aged 2 months were immunized with three consecutive doses of sIPV at 2, 3, and 4 months old to complete primary immunization. Out of the 1200 participants, 1129 received the 4th dose of sIPV as booster immunization. Immunogenicity was evaluated in 1100 participants. RESULTS: Seropositive rates of the anti-poliovirus type 1, 2, and 3 neutralizing antibodies were 99.9 %, 98.0 %, 98.2 %, respectively, with GMTs of 557.0, 146.1, 362.0 one year after primary vaccination. After booster vaccination between 18 and 24 months old, the seropositive rates for 3 types all reached 100.0 %, with GMTs of 8343.6, 5039.6, 5492.0, respectively. Particularly for the anti-poliovirus type 2 antibody, the GMT was 230.4 after primary immunization, maintained to 146.1 one year after primary immunization, and increased to as high as 5039.6 after booster vaccination. The GMT ratios between each batch groups after booster immunization were between 0.67 and 1.50, meeting the immunological equivalence criteria. The incidence rate of adverse reaction was 23.0 %, which was comparable to those in the phase Ⅲ trial but had a lower incidence. Furthermore, no SUSAR was reported in this study. INTERPRETATION: In conclusion, as the anti-poliovirus antibodies gradually waned one year post sIPV primary vaccination, especially the type 2 antibody waned to a very low level, suggesting the importance of the booster immunization for children at the age of 18-24 months old. The booster shot can greatly enhance the antibody level and protect children from the potential risk of infection with WPV and VDPV by supplementing the anti-poliovirus type 2 immunity gap in the current real world. Clinic Trial Registration. NCT04224519.
引用
- Yin Q, Zheng Y, Ying Z, et al. Immunogenicity and lot-to-lot consistency of booster shot with Sabin inactivated poliomyelitis vaccine in Chinese children aged 18-24 Months: A phase Ⅳ clinical trial. Vaccine. 2024. PMID: 38388236. doi:10.1016/j.vaccine.2024.02.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。